問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Surgery

Division of Hematology & Oncology

National Taiwan University Hospital Hsin-Chu Branch

Division of Hematology & Oncology

National Taiwan University Cancer Center

Division of Hematology & Oncology

更新時間：2023-09-19

張端瑩
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

136Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

張端瑩

List

241Cases

2012-05-15 - 2020-09-08

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2011-05-15 - 2013-11-15

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2014-03-31 - 2022-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2012-08-01 - 2015-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2012-09-01 - 2018-12-18

Phase III

A phase III randomized, double blind placebo controlled study of oral BKM120 in combination with fulvestrant, in the treatment of postmenopausal women with hormone receptor-positive HER2-negative locally advanced or metastatic breast cancer whose disease has progressed on or after aromatase inhibitor treatment

  • Condition/Disease

    locally advanced or metastatic breast cancer

  • Test Drug

    BKM120

Participate Sites
5Sites

Terminated5Sites

2020-02-25 - 2023-01-09

Phase III

EPIK-B2: A two part, Phase III, multicenter, randomized (1:1), double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with trastuzumab and pertuzumab as maintenance therapy in patients with HER2-positive advanced breast cancer with a PIK3CA mutation

  • Condition/Disease

    Advanced HER2+Breast Cancer

  • Test Drug

    Alpelisib (BYL719)

Participate Sites
4Sites

Recruiting4Sites

2019-02-28 - 2023-04-30

Phase II

A Phase II Randomized Study of the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Physician Choice Chemotherapy in Premenopausal or Perimenopausal Patients With Hormone Receptor-positive/ HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer

  • Condition/Disease

    Breast cancer

  • Test Drug

    KISQALI

Participate Sites
9Sites

Recruiting8Sites

劉良智
China Medical University Hospital-Taipei

未分科

陳訓徹
Linkou Chang Gung Medical Foundation

2018-07-02 - 2021-06-08

Phase II

A Phase II Open-label, Randomized, Three-arm, Multicenter Study of LAG525 Given in Combination With Spartalizumab (PDR001), or With Spartalizumab and Carboplatin, or With Carboplatin, as First or Second Line Therapy in Patients With Advanced Triple-negative Breast Cancer

  • Condition/Disease

    Advanced Triple-negative Breast Cancer

  • Test Drug

    LAG525、PDR001

Participate Sites
3Sites

Terminated3Sites

曾令民
Taipei Veterans General Hospital

2021-09-01 - 2023-08-09

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2012-05-23 - 2015-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

1 21 22 23 24 25
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB